Markets
Nvidia CEO Jensen Huang
(Justin Sullivan/Getty Images)

Nvidia analyst: “This is not over”

Trump blinked on some tariffs Wednesday, sending Nvidia’s shares higher by 19%. But the trade beef between the US and China remains a serious headwind for the chip giant.

Nvidia is once again the one of heaviest weights on the stock market Thursday — it’s head to head against Apple — as the tech shares that exploded yesterday on President Trump’s decision to walk back the bulk of global tariffs — at least for 90 days — generated the best day for stocks since 2008.

But the relief rally obscured that fact that Trump also jacked up the administration’s tariffs on China to 125%, a level that would essentially end much of the commerce between the world’s two biggest economies, a trade relationship that is the foundation for the global tech industry.

That poses a risk even to tech giants like Nvidia, whose main product, computer chips, are exempt from the Liberation Day tariffs, as those exceptions may not last.

“Tariff fears may have receded, but this is not over,” wrote Morgan Stanley analysts covering Nvidia, in note published on Thursday (emphasis added):

“Semiconductors were exempted from ‘liberation day’, but most industry participants are convinced that this just means semiconductor tariffs will be handled differently. We don’t know what that might look like, but our hope is that it would be phased in more gradually, assuming the end goal is more domestic manufacturing of semiconductors which takes multiple year lead times.

Pharmaceuticals were also initially exempt from the ‘liberation day’ tariffs, but recent comments from the president indicate that tariffs are still forthcoming. If there are tariffs on semiconductors, the TSMC wafers, and the HBM memory, would all be assessed a tariff. That would be something like 60% of cost of sales, which for a 75% gross margin data center business is about 15% of revenues; a 32% tariff would then be about a 5% tax, which would be pretty easily absorbed. This would be much larger for companies with more typical gross margins.

Earlier this week, US Trade Representative Jamieson Greer told the Senate Finance Committee that chips (along with pharma) were excluded from reciprocal tariffs because “we think they need their own investigations.”

Moreover, Nvidia — like every other corporation — is still at risk from a recession, should one show up.

“Is NVIDIA recession resistant? No, probably not, and that remains a risk. But the type of recession also matters, as demand for GPUs remains resilient — and we would say risks to that come more from the financing side than from anywhere else. Modest drift lower in [surveys of industrial activity], or slower consumer retail from tariffs, is not a problem for GPU spending, but financial strains in venture funding would be a problem.”

Yet Nvidia remains Morgan Stanley analysts’ top pick in the chip sector, given its strong business supplying the graphics processing units at the heart of the global AI investment boom. They have a price target of $162.50 on the stock, which implies a roughly 50% upside from where the stock is trading.

More Markets

See all Markets
markets

Eli Lilly’s GLP-1 pill hit nearly 1,400 prescriptions in first week

Eli Lilly rose after preliminary numbers cited by Wall Street analysts showed strong uptake of its new weight-loss pill.

The FDA approved Foundayo on April 1 and shipments began on April 9. In its first week, roughly 1,400 US prescriptions were written for the drug, according to IQVIA data cited by Deustche Bank analysts in a Friday note.

Novo Nordisk, Lilly’s rival in the GLP-1 market, released its GLP-1 pill earlier this year, and early signs show that it’s expanding the market, inviting patients who were turned off by weekly injections. Novo’s pill had a stronger first week than Lilly’s, with its Wegovy pill hitting 3,071 US prescriptions in the first four days after its launch on January 5..

Lilly’s pill has an advantage over Novo’s, which is that it can be taken at any time of day, with or without food. Lilly disclosed in a February regulatory filing that it had $1.5 billion worth of prelaunch inventory ready ahead of the FDA approval — which is about as much as analysts polled by FactSet expect it to sell this year.

Novo Nordisk, Lilly’s rival in the GLP-1 market, released its GLP-1 pill earlier this year, and early signs show that it’s expanding the market, inviting patients who were turned off by weekly injections. Novo’s pill had a stronger first week than Lilly’s, with its Wegovy pill hitting 3,071 US prescriptions in the first four days after its launch on January 5..

Lilly’s pill has an advantage over Novo’s, which is that it can be taken at any time of day, with or without food. Lilly disclosed in a February regulatory filing that it had $1.5 billion worth of prelaunch inventory ready ahead of the FDA approval — which is about as much as analysts polled by FactSet expect it to sell this year.

markets

Critical Metals jumps after Greenland’s government approves CRML to take majority control of the Tanbreez mining project

Critical Metals is up more than 25% in premarket trading on Friday after the critical mining company announced that it now owns 92.5% of the Tanbreez rare earth deposit following an approval from the government of Greenland.

With that latest government support, Critical Minerals added an additional 50.5% stake to its ownership, reportedly acquired from Rimbal Pty Ltd, per Bloomberg News. With access to eight heavy rare earth elements often used in consumer electronics and defense, the site is one of the world’s largest undeveloped rare earth deposits and a key source of rare earth supply outside of China, according to the company.

In Critical Metals’ press release, Chairman Tony Sage commented that the approval “removes the most significant structural overhang on the project and provides the clarity to advance Tanbreez to production with confidence,” especially as Tanbreez’s location offers a significant logistical advantage through its year-round direct shipping access, compared to rival projects.

With 92.5% of the project now vested in Critical Metals Corp., and the remainder owned by European Lithium Ltd., CRML now has full control of the project and is seeking to accelerate development there, with plans for a new international airport and a 150-tonne bulk sample program, which is slated for June 2026.

TOPSHOT-US-ENTERTAINMENT-STREAMING-NETFLIX

Netflix beats on Q1 revenue, issues downbeat Q2 forecast, and says Hastings will leave in June

It’s the streamer’s first earnings report since backing out of the Warner Bros. bidding war in February.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.